Abstract：Our study aimed to use the B. subtilis spores as vaccine antigen presenting vectors. We constructed a recombinant B. subtilis spores that can display recombinant Yersinia Pestis F1 antigen on the surface, then analyzed the immunogenicity and protective efficacy of the vaccine by performing animal experiments. The CotB gene from B. subtilis was inserted into pDG1664 integrational vector followed by ligation with F1 antigen gene; and then recombinant plasmids were integration into the genome of B. subtilis PY-79 by genetic homologous recombination. The methods of PCR, Western blot were used to identify the expression of F1 proteins presented on the surface of B. subtilis spores. Mice were immunized orally without adjuvants, then analyzed immunization by ELISA. The results showed that we successfully constructed the recombinant strains of B. subtilis which was integrated with F1 gene, and F1 proteins could be presented successfully on the surface of spores. Immunization of the recombinant spores can elicit high titer of specific IgG antibodies in mice. Above all, our study successfully recombined a B. Subtilis Spore-Based Plague Vaccine which could stably express F1 antigen on the spore coat, and mouse which was immunized with the recombinant B. subtilis could induce effective immune response. The recombinant spores can be used as a new type of plague candidate vaccine based on B. subtilis spore display system.
[1] Demeure CE, Derbise A, Carniel E. Oral vaccination against plague using Yersinia pseudotuberculosis[J]. Chem Biol Interac, 2017, 267:89-95. DOI: 10.1016/j.cbi.2016.03.030 [2] Sun W. Plague Vaccines: Status and Future[J]. Adv Exp Med Biol, 2016, 918: 313-360. DOI: 10.1007/978-94-024-0890-4_12 [3] Ducle H, Hong HA, Cutting SM. Germination of the spore in the gastrointestinal tract provides a novel route for heterologous antigen delivery[J]. Vaccine, 2003, 21(27-30):4215-4224. [4] Ducle H, Hong HA, Uyen NQ, et al. Intracellular fate and immunogenicity of B. subtilis spores[J]. Vaccine, 2004, 22(15/16):1873-1885. DOI: 10.1016/j.vaccine.2003.11.021 [5] Isticato R, Cangiano G, Tran HT, et al. Surface display of recombinant proteins on Bacillus subtilis spores[J]. J bacteriol, 2001, 183(21):6294-6301. DOI: 10.1128/JB.183.21.6294-6301.2001 [6] Lee S, Belitsky BR, Brown DW, et al. Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment C[J]. Vaccine, 2010, 28(41):6658-6665. DOI: 10.1016/j.vaccine.2010.08.016 [7] Zhou Z, Xia H, Hu X, et al. Immunogenicity of recombinant Bacillus subtilis spores expressing Clonorchis sinensis tegumental protein[J]. Parasitol Res, 2008, 102(2):293-297. DOI: 10.1007/s00436-007-0762-x [8] Zhou Z, Xia H, Hu X, et al. Oral administration of a Bacillus subtilis spore-based vaccine expressing Clonorchis sinensis tegumental protein 22.3 kDa confers protection against Clonorchis sinensis[J]. Vaccine, 2008, 26(15):1817-1825. DOI: 10.1016/j.vaccine.2008.02.015 [9] Zhao G, Miao Y, Guo Y, et al. Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine[J]. Hum Vaccin Immunother, 2014, 10(12): 3649-3658. DOI: 10.4161/hv.36122 [10] Henriques AO, Moran CP Jr. Structure, assembly, and function of the spore surface layers[J]. Annu Rev Microbiol, 2007, 61: 555-588. DOI: 10.1146/annurev.micro.61.080706.093224 [11] Liu H, Qiao H, Krajcikova D, et al. Physical interaction and assembly of Bacillus subtilis spore coat proteins CotE and CotZ studied by atomic force microscopy[J]. J Struct Biol, 2016, 195(2):245-251. DOI: 10.1016/j.jsb.2016.06.010 [12] Iwanicki A, Piatek I, Stasilojc M, et al. A system of vectors for Bacillus subtilis spore surface display[J]. Microb Cell Fact, 2014, 13(1):30. DOI: 10.1186/1475-2859-13-30 [13] Chen H, Tian R, Ni Z, et al. Surface display of the thermophilic lipase Tm1350 on the spore of Bacillus subtilis by the CotB anchor protein[J]. Extremophiles, 2015, 19(4):799-808. DOI: 10.1007/s00792-015-0755-0 [14] Bevins SN, Baroch JA, Nolte DL, et al. Yersinia pestis: examining wildlife plague surveillance in China and the USA[J]. Integr Zool, 2012, 7(1):99-109. DOI: 10.1111/j.1749-4877.2011.00277.x [15] Verma SK, Tuteja U. Plague vaccine development: current research and future trends[J]. Front Immunol, 2016, 7: 602. DOI: 10.3389/fimmu.2016.00602 [16] Liu L, Wei D, Qu Z, et al. A safety and immunogenicity study of a novel subunit plague vaccine in cynomolgus macaques[J]. J Appl Toxicol, 2018, 38(3):408-417. DOI: 10.1002/jat.3550 [17] Williamson ED, Oyston PC. Protecting against plague: towards a next-generation vaccine[J]. Exp Clin Immunogenet, 2013, 172(1):1-8. DOI: 10.1111/cei.12044 [18] Gupta G, Khan AA, Rao DN. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis[J]. Scand J Immunol, 2010, 71(3):186-198. DOI: 10.1111/j.1365-3083.2009.02365.x [19] Dankmeyer JL, Fast RL, Cote CK, et al. Multiple roles of Myd88 in the immune response to the plague F1-V vaccine and in protection against an aerosol challenge of Yersinia pestis CO92 in mice[J]. J Immunol Res, 2014, 2014: 341820. DOI: 10.1155/2014/341820 [20] Ali R, Naqvi RA, Kumar S, et al. Multiple antigen peptide containing B and T cell epitopes of F1 antigen of Yersinia pestis showed enhanced Th1 immune response in murine model[J]. Scand J Immunol, 2013, 77(5):361-371. DOI: 10.1111/sji.12042 [21] Levy Y, Flashner Y, Tidhar A, et al. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague[J]. Vaccine, 2011, 29(40):6866-6873. DOI: 10.1016/j.vaccine. 2011.07.059
2019, Vol. 35 
